Physician profile
William Bostock
NPI 1144361411
$516.62
in general payments reported to CMS, 2019-2025
15 companies · $50.89 in 2025
The $50.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.06 · 2021: $21.34 · 2022: $167 · 2023: $95.62 · 2024: $100 · 2025: $50.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70.15 | 2022-2024 | Farxiga, Breztri |
| Abbott Laboratories | $66.65 | 2022 | |
| Lilly USA, LLC | $49.52 | 2023-2024 | Mounjaro |
| Abbvie INC. | $45.32 | 2022-2024 | Vraylar |
| Amgen INC. | $41.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.00 | 2019 | |
| Astellas Pharma US INC | $37.36 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $35.58 | 2023-2025 | Shingrix, Pediarix, Bexsero |
| Novo Nordisk INC | $26.92 | 2022 | |
| Medtronic, INC. | $21.34 | 2021 | |
| Inspire Medical Systems, INC. | $19.36 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $16.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.48 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.46 | 2025 | Opsumit, Uptravi |
| Exact Sciences Corporation | $13.49 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bostock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.